Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Dec;41(12):2612–2615. doi: 10.1128/aac.41.12.2612

In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.

J L Muñoz Bellido 1, S Muñoz Criado 1, I García García 1, M A Alonso Manzanares 1, M N Gutiérrez Zufiaurre 1, J A García-Rodríguez 1
PMCID: PMC164178  PMID: 9420028

Abstract

The activities of ampicillin, ampicillin-sulbactam, amoxicillin, amoxicillin-clavulanic acid, ticarcillin, ticarcillin-clavulanic acid, piperacillin, piperacillin-tazobactam, aztreonam, and aztreonam-clavulanic against Stenotrophomonas maltophilia strains for which the MICs of penicillins and commercially available beta-lactam-beta-lactamase inhibitor combinations were higher than the breakpoints usually recommended for Pseudomonas aeruginosa in commercially available broth microdilution methods were tested by the agar diffusion, agar dilution, and broth microdilution methods. Time-kill curve studies were performed when discrepancies between these methods were observed. The MICs obtained by the commercially available broth microdilution method, the agar dilution method, and the broth microdilution method were almost identical. Twenty-five percent of the strains tested showed inhibition diameters of > or =15 mm for ticarcillin-clavulanic acid, and 43.7% of the strains tested showed inhibition diameters of > or =18 mm for piperacillin-tazobactam by the agar diffusion method. The time-kill curves for these strains confirmed the results obtained by dilution methods. Aztreonam-clavulanic acid (2:1) at concentrations of < or =16 microg/ml inhibited all of these strains (MIC range, 1 to 16 microg/ml). The time-kill curves confirmed this activity. The addition of piperacillin to this combination did not modify the MICs. The combination aztreonam-clavulanic acid-ticarcillin was two- to fourfold more active than aztreonam-clavulanic acid alone. We studied the inhibitory and bactericidal activities of the two most active combinations (aztreonam-clavulanic acid and aztreonam-clavulanic acid-ticarcillin) against the standard inoculum and 10 and 50 times the standard inoculum. Inoculum modifications did not modify the MICs. Both combinations showed good bactericidal activity against the standard inoculum. With 10 times the standard inoculum, minimum bactericidal concentration (MBC) results were heterogeneous (for 55% of the strains, MBCs were between the MIC and 4-fold the MIC, and for 45% of the strains MBCs were between 8- and >32-fold the MIC). With 50 times the standard inoculum, MBCs were at least 32-fold the MICs for all the strains tested.

Full Text

The Full Text of this article is available as a PDF (149.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arpi M., Victor M. A., Mortensen I., Gottschau A., Bruun B. In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods. APMIS. 1996 Feb;104(2):108–114. [PubMed] [Google Scholar]
  2. Bush K., Jacoby G. A., Medeiros A. A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995 Jun;39(6):1211–1233. doi: 10.1128/aac.39.6.1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cullmann W. Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates. Chemotherapy. 1991;37(4):246–250. doi: 10.1159/000238862. [DOI] [PubMed] [Google Scholar]
  4. Elting L. S., Khardori N., Bodey G. P., Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 1990 Mar;11(3):134–138. doi: 10.1086/646136. [DOI] [PubMed] [Google Scholar]
  5. García-Rodríguez J. A., García Sánchez J. E., García García M. I., García Sánchez E., Muñoz Bellido J. L. Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of beta-lactam/beta-lactamase inhibitor combinations. Diagn Microbiol Infect Dis. 1991 May-Jun;14(3):239–243. doi: 10.1016/0732-8893(91)90038-h. [DOI] [PubMed] [Google Scholar]
  6. García-Rodríguez J. A., García Sánchez J. E., Muñoz Bellido J. L., García García M. I., García Sánchez E. Kinetics of antimicrobial activity of aztreonam/clavulanic acid (2:1) against Xanthomonas maltophilia. J Antimicrob Chemother. 1991 Apr;27(4):552–554. doi: 10.1093/jac/27.4.552. [DOI] [PubMed] [Google Scholar]
  7. Liu P. Y., Lau Y. J., Hu B. S., Shyr J. M., Shi Z. Y., Tsai W. S., Lin Y. H., Tseng C. Y. Comparison of susceptibility to extended-spectrum beta-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units. Diagn Microbiol Infect Dis. 1995 Jul;22(3):285–291. doi: 10.1016/0732-8893(95)00096-s. [DOI] [PubMed] [Google Scholar]
  8. Paton R., Miles R. S., Amyes S. G. Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia. Antimicrob Agents Chemother. 1994 Sep;38(9):2143–2149. doi: 10.1128/aac.38.9.2143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Poulos C. D., Matsumura S. O., Willey B. M., Low D. E., McGeer A. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother. 1995 Oct;39(10):2220–2223. doi: 10.1128/aac.39.10.2220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Smit W. J., Boquest A. L., Geddes J. E., Tosolini F. A. The antibiotic susceptibilities of Xanthomonas maltophilia and their relation to clinical management. Pathology. 1994 Jul;26(3):321–324. doi: 10.1080/00313029400169751. [DOI] [PubMed] [Google Scholar]
  11. Vartivarian S., Anaissie E., Bodey G., Sprigg H., Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother. 1994 Mar;38(3):624–627. doi: 10.1128/aac.38.3.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Yamazaki E., Ishii J., Sato K., Nakae T. The barrier function of the outer membrane of Pseudomonas maltophilia in the diffusion of saccharides and beta-lactam antibiotics. FEMS Microbiol Lett. 1989 Jul 1;51(1):85–88. doi: 10.1016/0378-1097(89)90082-7. [DOI] [PubMed] [Google Scholar]
  13. Yao J. D., Louie M., Louie L., Goodfellow J., Simor A. E. Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas (Xanthomonas) maltophilia. J Clin Microbiol. 1995 May;33(5):1428–1430. doi: 10.1128/jcm.33.5.1428-1430.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES